S&P 500   4,164.00 (+1.29%)
DOW   34,156.69 (+0.78%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
S&P 500   4,164.00 (+1.29%)
DOW   34,156.69 (+0.78%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
S&P 500   4,164.00 (+1.29%)
DOW   34,156.69 (+0.78%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
S&P 500   4,164.00 (+1.29%)
DOW   34,156.69 (+0.78%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)

Edwards Life Sciences Stock Disaster Could Be Your Bounty

Key Points

  • The strong U.S. dollar impacted its aortic valve sales to 1% YoY growth compared to 5% in constant currency as it sells its products to almost 100 countries, while based in Irvine, CA
  • Despite being down (-46%) for the year, Edwards Life Sciences stock is still overvalued compared to competitors like Medtronic, Boston Scientific and Becton Dickinson underscoring that valuation, not earnings is what drove the (-20%) sell-off in reaction to Q3 2022 earnings
  • Rising costs, COVID restraints, and hospital staffing shortages all led to the earnings shortfall and subsequent panic sell-off in shares of EW
  • These headwinds all seem transitory in light of the epidemic of growing heart disease among the aging population, which Edwards Life Sciences is a key player   
  • 5 stocks we like better than Edwards Lifesciences
Edwards Life Sciences Stock Disaster Could Be Your BountyHeart disease equipment maker Edwards Life Sciences (NYSE: EW) stock has fallen (-46%) on the year after a disastrous reaction to its Q3 2022 earnings report. The maker of heart valve systems and repair products for both surgical and transcatheter therapies reported a small miss and lowered its full-year 2022 guidance and got punished hard for it. While it may appear to be an overreaction at first, a glance at its valuation compared to peers indicates just how expensive shares were heading into the earnings report and is still expensive after shaving (-20%) of its share price afterward. A closer look at the historical price action of the shares illustrates the punishment that shareholders have endured as its stock has gone through three back-to-back stock plunges after each bounce attempt failed as shares lost nearly half its value from the top. Cost inflation and interest rate headwinds made a material impact on its recent earnings. While based in Irvine, California, Edwards sells its products in almost 100 countries worldwide. The strong U.S. dollar definitely impacted its earnings as its aortic valve sales rose 1% but actually 5% in constant currency in its recent quarter. Hospital staffing shortages in the U.S. and COVID restrictions in Japan contributed to the shortfall as well as the lowered guidance for the rest of 2022. These constraints appear to be more transitory than permanent. Underneath the gloomy sentiment is a silver lining as Edwards is a key player in the growing epidemic and business of combating heart disease among the aging population.

Addressing Heart Disease

Heart disease is the leading cause of death in the U.S. responsible for 697,000 deaths in 2020, one out of every five deaths. Aortic stenosis (AS) is the narrowing of the aortic valve caused by calcium buildup over time. Risk factors for the development of AS include diabetes, chronic kidney disease, high blood pressure and abnormal lipids. This can cause a blockage of blood flow to the body thereby forcing the heart to work harder. It’s the most common valvular heart disease and is present in nearly 5% of the population at age 65 and increases with age. Transcatheter aortic valve replacement (TAVR) or valve implementation (TAVI) is used to treat AS. The procedure replaces a damaged aortic valve with a manufactured valve made of pig or cattle (bovine) tissue. Edwards currently sells the SAPIEN 3, SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve System. Its RESILIA tissue contains advanced calcium blocking technology which has the potential to improve valve longevity and reduce intervention. Heart valves usually last up to 10-years. RESILIA tissue has been shown to lower calcium content by 72%. Edwards also utilizes RESILIA in many of its surgical valves for treatment of mitral valve disease, when the valves don’t close tightly in the left heart chambers causing blood to leak backwards.


Valuation, Not Earnings Killed the Stock

On Oct. 22, 2022, Edwards released its fiscal third-quarter 2022 results for the quarter ending September 2022. The Company reported an earnings-per-share (EPS) profit of $0.61 excluding non-recurring items versus consensus analyst estimates for a profit of $0.62, a (-1%) miss. Revenues rose 0.7% year-over-year (YoY) to $1.32 billion missing analyst estimates for $1.33 billion. Discontinued HARPOON program resulted in a charge of $0.07 per share. Transcatheter Aortic Valve Replacement (TAVR) sales rose 1% YoY to $862 million or 6% on a constant currency basis. Sales were mostly impacted by hospital staffing shortages in the U.S. and COVID headwinds in Japan. Edwards Life Sciences CEO Michael Mussallem commented, "The third quarter strengthened our conviction in our company's patient-focused innovation strategy. Despite a challenging macro environment, our team made significant progress advancing our breakthrough technologies. Our rigorous evidence generation has resulted in new global product approvals of innovative therapies, which will enable us to reach many more patients." Edwards also announced it executed an accelerated $750 million stock buyback to bring total share buybacks to over $1.7 billion in 2022. There is still another $900 million remaining in the share repurchase authorization approved by its Board of Directors.

 

Edwards Life Sciences Stock Disaster Could Be Your Bounty

Three Strikes and Bulls are Out?

The weekly chart on EW is painful to watch as it got hit hard with two consecutive bearish patterns back to back. First the head and shoulders pattern triggered when the neckline collapse at $112.84 to fall down to $85.58. EW then staged a rally off those lows up to $107.92, which gave the bulls hope for a further rally. Unfortunately, it was a trap as the bear flag that triggered a rug pull on the breakdown of $98.34 causing shares to sink to $80.69 before staging a small rally up to $89.17 in anticipation of earnings. Unfortunately (again) the Q3 2022 earnings game up short causing the stock to plunged towards the pandemic market structure low trigger level at $70.92 on the heaviest weekly volume since the pandemic lows, which could be a sign of capitulation. Three strikes comprised of a weekly head and shoulders breakdown, a bear flag breakdown, and an earnings disaster collapse could mean the bulls are throwing in the towel and out. Pullbacks can be watch for at the $68.40 weekly market structure low trigger, 67.50 support level, $60.48, $55.23 and 51.51 support levels.

Pipeline Approvals to Drive Growth

Edwards received U.S. FDA and European CE Mark approval for PASCAL Precision for treatment of degenerative mitral regurgitation in September and August, respectively. The system is designed for transcatheter-based-edge-to-edge leaflet repair for sufferers of mitral and tricuspid regurgitation. The Company has been approved to begin selling the SAPIEN 3 Ultra RESILIA valve in the U.S. Enrollment accelerated in its 2 TAVR pivotal trials for its next-gen SAPIEN X4. CEO Mussallem commented, “These transformative developments reinforce our confidence in the continued growth of transcatheter-based structural heart inventive. We will continue to aggressively pursue breakthrough technologies with the potential to help even a broader group of patients and in turn drive significant future value.”

Shares Have More Room to Fall

Edwards lowered its guidance for fiscal full-year 2022 EPS of $2.40 to $2.50 from $2.50 to $2.65 versus $2.52 consensus analyst estimates. Full-year 2022 revenues are expected to come in between $5.35 billion to $5.55 billion versus $5.47 billion consensus analyst estimates. Edwards Lifesciences shares trade at 28X forward earnings, nearly twice that of rival Medtronic (NYSE: MDT) trading at 15X forward earnings. It still trades at a higher valuation than other medical device maker peers like Boston Scientific (NYSE: BSX) at 24X, Becton Dickinson at (NYSE: BDX) at 19.3X, and St. Jude Medical owned by Abbott Labs (NYSE: ABT) at 18.5X. The market is repricing its valuation leaving it more room to fall to get in line with its peer trading closer to a 18X to 24X forward earnings. It becomes a value play once shares fall under the 20X forward earnings mark.  

 

Should you invest $1,000 in Edwards Lifesciences right now?

Before you consider Edwards Lifesciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.

While Edwards Lifesciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Beginners Guide To Retirement Stocks Cover

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Edwards Lifesciences (EW)
2.8452 of 5 stars
$80.04+1.2%N/A32.80Hold$89.74
Becton, Dickinson and (BDX)
3.0665 of 5 stars
$253.19+1.2%1.44%47.77Moderate Buy$275.70
Boston Scientific (BSX)
2.5409 of 5 stars
$48.09+0.9%N/A106.87Buy$51.27
Medtronic (MDT)
2.7222 of 5 stars
$86.58+1.6%3.14%26.89Hold$94.25
Abbott Laboratories (ABT)
3.41 of 5 stars
$111.99+1.1%1.82%28.64Moderate Buy$125.63
Compare These Stocks  Add These Stocks to My Watchlist 

Jea Yu

About Jea Yu

Contributing Author: Trading Strategies

With over 20 years of active participation and analysis of the US equities, options and futures markets, Mr. Yu brings fresh insights into the workings of the financial markets. He has published four books by esteemed publishers McGraw-Hill, John Wiley & Sons, Marketplace Books and Bloomberg Press. His brainchild, the Underground Trader, was voted Forbes Best of the Web for four consecutive years under the active trader category. He has been a featured speaker all over the country at various expos and seminars who enjoys a standing-room-only reception in the largest convention halls from New York to Las Vegas. He has been quoted and featured in USA Today, Wall Street Journal, Traders Magazine and the Financial Times and various trade publications like Stocks & Commodities, Active Trader and Online Investor. Mr. Yu has a B.A. in Liberal Arts and minor in Business Administration from the University of Maryland.
Contact Jea Yu via email at JeaYu21@gmail.com.

Featured Articles and Offers

Search Headlines: